Samsung Electronics Co., Ltd.

Jae Woong Hwang

Kwang Ho Cheong

Seung Hyun Lee

Mi Young Cho

Powei Lin

Young Jun Koh

Christina Yi

Jung Wook Lee

Saet Byoul Lee

Ji Min Lee

Kyung Ah Kim

Bo Gyou Kim

Min-Kyung Kim

Seung Ja Oh

Geun Woong Kim

Han Na Choi

Lin Powei

There are provided an anti-c-Met/anti-Her2 bispecific antibody, and a method for preventing and/or treating cancer using the same.

Bispecific anti-Cmet/anti-Her2 antibodies

An anti-EGFR/anti-HER3 antibody or antigen binding fragment thereof, and a method of preventing and/or treating a cancer using the same.

Anti-cMet/anti-EGFR/anti-HER3 multispecific antibodies and use thereof

An anti-HER2 antibody, an anti-c-Met/anti-HER2 bispecific antibody including the same, method for preparing same, and a method of preventing and/or treating a cancer using the same are provided.

Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same

A biomarker Hsp90 for predicting an efficacy of a c-Met inhibitor, selecting a subject for application of a c-Met inhibitor, or monitoring an efficacy of a c-Met inhibitor, and a relevant method of using Hsp90.

Biomarker Hsp90 for predicting effect of a c-Met inhibitor

An anti-EGFR scFV fragment, an anti-c-Met/anti-EGFR bispecific antibody including the same, and a method of preventing and/or treating a cancer using the same are provided.

Anti-EGFR antibody and anti-c-Met/anti-EGFR bispecific antibodies comprising the same

There are provided an anti-c-Met/anti-EGFR bispecific antibody, a method for treating cancer using the same, and an anti-EGFR scFv fragment.

Anti-c-Met/anti-EGFR bispecific antibodies

An anti-EGFR/anti-HER2 bispecific antibody including an anti-EGFR DARPin and an anti-HER2 antibody, a pharmaceutical composition including the bispecific antibody, a method of preparing the bispecific antibody, and a method of reducing a side effect and/or enhancing efficacy of an anti-HER2 antibody using an anti-EGFR DARPin.

Anti-EGFR/anti-HER2 bispecific antibodies with anti-EGFR DARPins

A method of target membrane protein depletion comprising treating a cell with a dual binding molecule comprising a first binding domain which binds to a driver membrane protein and a second binding domain which binds to a target membrane protein, wherein the cell comprises a cell membrane, and the driver membrane protein and target membrane protein are associated with the cell membrane where the target membrane protein positions, and are internalized into a cell and degraded when the first binding domain of the dual binding molecule binds the driver membrane protein; as well as related methods and compositions.

Method of target membrane protein depletion

A bispecific chimeric protein including a designed ankyrin repeat protein (DARPin), and an IgG antibody, an scFv-Fc antibody fragment, or a combination thereof, linked to the DARPin; a method for treating or preventing cancer using the same; and related methods and compositions.

Growing community of inventors

Seoul, South Korea

Jae Woong Hwang